Answers are grounded in this paper and cite their sources.
β⁻-emitting ¹⁷⁷Lu-octreotate is an approved somatostatin receptor subtype 2 (SSTR2)–directed peptide receptor radionuclide therapy for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). However,¹⁷⁷Lu-octreotate has fast pharmacokinetics, requiring up to 4 treatment doses. Moreover, ¹⁷⁷Lu is less than ideal for theranostics because of the low branching ratio of its γ-emissions, which limits its SPECT imaging capability. Compared with ¹⁷⁷Lu, ⁶⁷Cu has better decay properties for use as a theranostic. Here, we report the preclinical evaluation of a long-lived somatostatin analog, [⁶⁷Cu]Cu-DOTA-Evans blue-TATE (EB-TATE), against SSTR2-positive NETs. Methods: The in vitro cytotoxicity of [⁶⁷Cu]Cu-EB-TATE was investigated on 2-dimensional cells and 3-dimensional spheroids. In vivo pharmacokinetics and dosimetry were studied in healthy BALB/c mice, whereas ex vivo biodistribution, micro-SPECT/CT imaging, and therapy studies were done on athymic nude mice bearing QGP1.SSTR2 and BON1.SSTR2 xenografts. Therapeutic efficacy was compared with [¹⁷⁷Lu]Lu-EB-TATE. Results: Projected human effective doses of [⁶⁷Cu]Cu-EB-TATE for male (0.066 mSv/MBq) and female (0.085 mSv/MBq) patients are tolerable. In vivo micro-SPECT/CT imaging of SSTR2-positive xenografts with [⁶⁷Cu]Cu-EB-TATE showed tumor-specific uptake and prolonged accumulation. Biodistribution showed tumor accumulation, with concurrent clearance from major organs over a period of 72 h. [⁶⁷Cu]Cu-EB-TATE was more effective (60%) at eliminating tumors that were smaller than 50 mm³ within the first 15 d of therapy than was [¹⁷⁷Lu]Lu-EB-TATE (20%) after treatment with 2 doses of 15 MBq administered 10 d apart. Mean survival of [⁶⁷Cu]Cu-EB-TATE–treated groups was 90 d and more than 90 d, whereas that of [¹⁷⁷Lu]Lu-EB-TATE was more than 90 d and 89 d against vehicle control groups (26 d and 53 d), for QGP1.SSTR2 and BON1.SSTR2 xenografts, respectively. Conclusion: [⁶⁷Cu]Cu-EB-TATE exhibited high SSTR2-positive NET uptake and retention, with favorable dosimetry and SPECT/CT imaging capabilities. The antitumor efficacy of [⁶⁷Cu]Cu-EB-TATE is comparable to that of [¹⁷⁷Lu]Lu-EB-TATE, with [⁶⁷Cu]Cu-EB-TATE being slightly more effective than [¹⁷⁷Lu]Lu-EB-TATE for complete remission of small tumors. [⁶⁷Cu]Cu-EB-TATE therefore warrants clinical development.
No takes yet. Share an insight, caveat, or question.
Njotu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: